findmyKOL
Clinical trialNCT00008463CompletedPhase 2Interventional

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment132HIV InfectionsHepatitis C
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to see if treatment with PEG-interferon-alfa-2a (PEG-IFN) plus ribavirin is a more effective treatment for hepatitis C virus (HCV) than interferon-alfa-2a (IFN) plus ribavirin for patients infected with both HCV and HIV. The study will also compare the 2 regimens to see which has fewer side effects. HCV infection is common in patients infected with HIV. Patients infected with both HIV and HCV viruses seem to have more severe hepatitis C. A combination of IFN and ribavirin has been shown to lessen the severity of HCV. PEG-IFN is a modified form of IFN that stays in the blood longer, which means that patients would not have to take the treatment as often. This study will compare the safety and effectiveness of PEG-IFN to IFN when each is combined with ribavirin.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Ucsd, Avrc Crs

    San Diego, California, United States

  • Ucsf Aids Crs

    San Francisco, California, United States

  • University of Colorado Hospital Crs

    Aurora, Colorado, United States

  • Univ. of Miami Aids Crs

    Miami, Florida, United States

  • the Ponce de Leon Ctr. Crs

    Atlanta, Georgia, United States

  • Univ. of Hawaii at Manoa, Leahi Hosp.

    Honolulu, Hawaii, United States

  • Indiana Univ. School of Medicine, Infectious Disease Research Clinic

    Indianapolis, Indiana, United States

  • Indiana Univ. School of Medicine, Wishard Memorial

    Indianapolis, Indiana, United States

  • Methodist Hosp. of Indiana

    Indianapolis, Indiana, United States

  • Univ. of Iowa Healthcare, Div. of Infectious Diseases

    Iowa City, Iowa, United States

  • Beth Israel Deaconess Med. Ctr., Actg Crs

    Boston, Massachusetts, United States

  • Bmc Actg Crs

    Boston, Massachusetts, United States

  • Brigham and Women'S Hosp. Actg Crs

    Boston, Massachusetts, United States

  • Massachusetts General Hospital Actg Crs

    Boston, Massachusetts, United States

  • University of Minnesota, Actu

    Minneapolis, Minnesota, United States

  • Beth Israel Med. Ctr., Actu

    New York, New York, United States

  • Hiv Prevention & Treatment Crs

    New York, New York, United States

  • Mt. Sinai Med. Ctr. A0404 Crs

    New York, New York, United States

  • Ny Univ. Hiv/aids Crs

    New York, New York, United States

  • Aids Care Crs

    Rochester, New York, United States

  • Univ. of Rochester Actg Crs

    Rochester, New York, United States

  • Univ. of Cincinnati Crs

    Cincinnati, Ohio, United States

  • Philadelphia Veterans Admin. Med. Ctr. A6205 Crs

    Philadelphia, Pennsylvania, United States

  • Univ. of Texas Southwestern Med. Ctr., Amelia Court Continuity Clinic

    Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Interferon alfa-2aPeginterferon alfa-2a →Ribavirin →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Nov 2000
Primary completion
—
Completion
31 Aug 2006
Last update posted
1 Nov 2021
Registered enrollment
132
Registry id
NCT00008463
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.